Test Details
Methodology
SNaPshot Multiplex PCR (primer extension-based method)
Result Turnaround Time
5 - 7 days
Use
KRAS is a guanosine triphosphate (GTP) binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival and differentiation. Mutations in the KRAS oncogene are frequently found in human cancers. They are common in pancreatic, colorectal, lung, gallbladder, bile duct and thyroid cancer. This assay will detect KRAS mutations in exons 2, 3 and 4, allowing the determination of drug response.
Special Instructions
Provide a copy of the pathology report; the KRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363.
Specimen Requirements
Limitations
This assay is able to detect 5% mutation in a background of wild-type DNA.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
References
Specimen
Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides
Volume
Formalin-fixed, paraffin-embedded tissue block or four unstained slides and one matching H&E-stained slide at 5 µM
Minimum Volume
Two unstained slides and one matching H&E-stained slide at 5 μM (samples with >4 mm² and ≥50% tumor content are preferred)
Container
FFPE tissue blocks or slides
Storage Instructions
Maintain blocks and slides at room temperature.
Causes for Rejection
Tumor block containing no tumor tissue; broken or stained slides